{"id":"alpha-glucosidase-inhibitor","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)"},{"rate":"10–20","effect":"Abdominal pain"},{"rate":"5–15","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL4297879","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs competitively inhibit enzymes (alpha-glucosidases) on the intestinal brush border that break down disaccharides and oligosaccharides into monosaccharides. By delaying carbohydrate hydrolysis and absorption, they reduce the rate at which glucose enters the bloodstream after meals, thereby lowering postprandial glucose excursions in patients with type 2 diabetes.","oneSentence":"Alpha-glucosidase inhibitors slow the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose spikes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:11.838Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT01301833","phase":"PHASE3","title":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-02","conditions":"Type 2 Diabetes Mellitus","enrollment":462},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT01242202","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":113},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT05711784","phase":"NA","title":"A Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract)","status":"COMPLETED","sponsor":"NovoBliss Research Pvt Ltd","startDate":"2023-02-22","conditions":"Body Weight in the Overweight and Obese Class - I Population","enrollment":66},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT06218342","phase":"PHASE4","title":"Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-02-15","conditions":"Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":156},{"nctId":"NCT05542849","phase":"PHASE4","title":"The Efficacy and Tolerability of Acarbose in Healthy Individuals","status":"COMPLETED","sponsor":"AgelessRx","startDate":"2022-08-10","conditions":"Tolerance, Side Effect, Glucose Response","enrollment":15},{"nctId":"NCT05249621","phase":"PHASE1","title":"A Randomized Phase 1 of of MZE001 in Healthy Volunteers","status":"COMPLETED","sponsor":"Maze Therapeutics","startDate":"2022-02-07","conditions":"Healthy","enrollment":121},{"nctId":"NCT03861039","phase":"PHASE3","title":"A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-03-30","conditions":"Type 2 Diabetes Mellitus","enrollment":443},{"nctId":"NCT01914133","phase":"PHASE2","title":"Acarbose and Older Adults With Postprandial Hypotension","status":"COMPLETED","sponsor":"Kenneth Madden","startDate":"2014-01","conditions":"Other Specified Hypotension, Syncope","enrollment":42},{"nctId":"NCT02730377","phase":"PHASE4","title":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-03-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1991},{"nctId":"NCT03241303","phase":"NA","title":"Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2017-08-01","conditions":"Glucose Metabolism Disorders","enrollment":15},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT00212017","phase":"NA","title":"Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT","status":"TERMINATED","sponsor":"National Cerebral and Cardiovascular Center, Japan","startDate":"2005-04","conditions":"Impaired Glucose Tolerance, Myocardial Infarction","enrollment":3000},{"nctId":"NCT02357225","phase":"EARLY_PHASE1","title":"A Pilot Study of Pyridostigmine in Pompe Disease","status":"TERMINATED","sponsor":"University of Florida","startDate":"2015-08","conditions":"Pompe Disease","enrollment":2},{"nctId":"NCT02879955","phase":"NA","title":"Carbohydrates and Gut Hormones After Gastric Bypass Surgery","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2016-08","conditions":"Overweight","enrollment":20},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":"Type 2 Diabetes Mellitus","enrollment":3453},{"nctId":"NCT01777282","phase":"PHASE3","title":"A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-23","conditions":"Diabetes Mellitus","enrollment":374},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT01077323","phase":"","title":"A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)","enrollment":363766},{"nctId":"NCT01468181","phase":"PHASE3","title":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":394},{"nctId":"NCT01421459","phase":"PHASE3","title":"A Study in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":759},{"nctId":"NCT01106651","phase":"PHASE3","title":"A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":716},{"nctId":"NCT01368081","phase":"PHASE3","title":"Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1162},{"nctId":"NCT01204294","phase":"PHASE3","title":"Comprehensive Add on Study in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-09","conditions":"Diabetes Mellitus, Type 2","enrollment":574},{"nctId":"NCT02015780","phase":"PHASE3","title":"Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":""},{"nctId":"NCT01503008","phase":"NA","title":"Proteus Sustained Behavior Change Study","status":"WITHDRAWN","sponsor":"Proteus Digital Health, Inc.","startDate":"2012-02","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00949442","phase":"PHASE4","title":"Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00213122","phase":"PHASE3","title":"Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin","status":"COMPLETED","sponsor":"Sanwa Kagaku Kenkyusho Co., Ltd.","startDate":"","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00213070","phase":"PHASE3","title":"Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment","status":"COMPLETED","sponsor":"Sanwa Kagaku Kenkyusho Co., Ltd.","startDate":"","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00213109","phase":"PHASE3","title":"Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment","status":"COMPLETED","sponsor":"Sanwa Kagaku Kenkyusho Co., Ltd.","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ALTERED STATE OF CONSCIOUSNESS"},{"count":1,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":1,"reaction":"CEREBRAL INFARCTION"},{"count":1,"reaction":"CONSTIPATION"},{"count":1,"reaction":"DIABETES MELLITUS"},{"count":1,"reaction":"DIABETES MELLITUS INADEQUATE CONTROL"},{"count":1,"reaction":"DIABETIC KETOACIDOSIS"},{"count":1,"reaction":"GLYCOSYLATED HAEMOGLOBIN INCREASED"},{"count":1,"reaction":"INSOMNIA"},{"count":1,"reaction":"NEUROSIS"}],"_approvalHistory":[],"publicationCount":1466,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"alpha-glucosidase inhibitor","genericName":"alpha-glucosidase inhibitor","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alpha-glucosidase inhibitors slow the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose spikes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}